Comparing the safety and efficacy of vibegron, mirabegron and tolterodine in patients with overactive bladder: a systematic review and network meta-analysis.
R Mohamed-Ahmed, A Rantell, D Robinson
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and network meta-analysis evaluated the safety and efficacy of vibegron, mirabegron, and tolterodine in patients with overactive bladder (OAB). Analyzing data from five studies involving 5,317 patients, vibegron showed a greater improvement in episodes of urinary urgency compared to both mirabegron and tolterodine. The findings suggest vibegron may be a more effective option for managing OAB symptoms.
Key findings
- Vibegron demonstrated a greater improvement in urinary urgency episodes compared to placebo, tolterodine, and mirabegron.
- Vibegron ranked favorably for reducing episodes of urinary incontinence and increasing maximum voided volume.
- Mirabegron showed a greater improvement in reducing urinary frequency episodes over 24 hours.
- Vibegron had the highest incidence of constipation among the treatments.
Why it matters
Understanding the comparative efficacy and safety of these medications is crucial for clinicians managing OAB, as it can guide treatment decisions and improve patient outcomes. The findings may influence prescribing practices and patient education regarding treatment options.